Explicit AI language can clarify an insurer’s stated approach to intellectual property claims. For enterprise leaders, the separate question is whether the underlying AI-assisted activity can be substantiated with reliable records.
Executive takeaways
- Check the applicable contract. An insurer’s announcement is not the policy wording governing an organisation’s exposure.
- Test one material workflow before expanding an evidence programme. Establish which inputs, versions, supplier commitments and release decisions can be reconstructed, and which cannot.
- Match evidence to the decision. Information useful before underwriting or renewal is not necessarily sufficient to reconstruct a disputed output after publication; neither purpose guarantees coverage or better terms.
An AI clause cannot reconstruct a disputed workflow
When an enterprise publishes AI-assisted material and a rights holder subsequently alleges infringement, the organisation may have a supplier agreement and publication policy yet remain unable to identify which source asset entered the process or which output version was approved. That creates an operational evidence problem independent of what its insurance policy says about artificial intelligence (AI). The policy governs the coverage question; operational records support factual reconstruction.
In September 2026, specialist insurance provider CFC announced affirmative AI coverage in its intellectual property (IP) policy: wording intended to state explicitly how AI involvement is treated rather than leave that issue implicit.[1] According to CFC, otherwise qualifying IP claims can remain covered when AI is involved. This reflects CFC’s stated product position, not a determination about any executed contract or adjudicated claim.
For the Board, the practical decision is whether management can support its account of a material AI-assisted activity before it relies on that account in an insurance submission or an IP dispute. Begin with one workflow and a defined evidence question, not an enterprise-wide assurance claim.
This article concerns insurance for risks arising from an organisation’s use of AI, not an insurer’s own use of AI to make underwriting decisions.
CFC’s public statements establish intent, not contractual outcomes
CFC’s 23 September announcement says its updated IP wording is designed to reduce ambiguity without changing the policy’s fundamental scope. It identifies possible exposure through training data, underlying technology and generated outputs, and observes that allegations may involve the business deploying AI rather than solely its technology supplier.[1] Those are the insurer’s descriptions of its wording and risk outlook; they are not judicial findings.
The change followed CFC’s 25 June programme announcing explicit AI language across seven product categories, including IP.[2] An August explainer discusses ownership, input rights and supplier contractual limits; its statements about how frequently providers limit liability are CFC observations, not findings from an independently reviewed contract sample.[3] CFC’s 30 September illustrative material also cautions that availability, terms and exclusions can vary. Its IP example involves an AI software developer confronting a patent allegation—not the AI-assisted marketing publication considered below.[4]
The limits matter. None of these pages supplies the operative wording of an executed IP policy. Nor does the announcement establish availability to a particular business in India, the UK, the EU, the US or elsewhere. Applicable endorsements, insured entities, exclusions, territorial conditions and law require contract-specific examination.
Start with the activity and the question the evidence must answer
A generic assertion that an organisation uses AI responsibly does not identify its IP exposure. Developing or adapting a model, retrieving source material and approving a published output can involve different actors, rights and records. A model-provider indemnity does not establish what a customer’s retrieval layer selected, or what its marketing team approved.
ODA3 Institute proposes an activity-to-evidence chain: deployment activity → potential rights conflict → possible business consequence → relevant control → retained evidence → bounded factual conclusion → unresolved questions. It is a method for structuring an examination, not a CFC underwriting requirement.
| Executive or underwriting question | Evidence to examine | What it may establish | What remains unresolved |
|---|---|---|---|
| Which entity and activity create the exposure? | Workflow map, supplier and entity inventory | Declared participants, activities and boundaries for a given period | Undeclared activity or changed suppliers |
| Which material entered the process? | Source identifiers, retrieval records, licence metadata | Recorded material and a possible source-to-output link | Legal sufficiency of rights; uncaptured inputs |
| Which system produced the output? | Model/provider identifiers, configurations, change logs | Recorded system state at the relevant time | Undocumented upstream or shadow changes |
| Did source restrictions operate? | Access rules, scoped tests, exceptions | Control operation under examined conditions | Behaviour beyond the tested conditions |
| Who reviewed and released the output? | Versions, reviewer context, approvals, publication log | Recorded sequence of approval and release | Adequacy of legal review and missing context |
| What did the supplier undertake? | Contracts, indemnities, change notices | Contractual representations and stated conditions | Whether these obligations apply to the particular dispute |
A source inventory without rights records may support provenance but not permission. These are different propositions requiring different evidence. A cryptographic hash can help match retained file contents; it creates no licence or permission. A test can document behaviour under specified conditions, not all subsequent behaviour.
Underwriting and claims reconstruction need different evidence
Before binding or renewal, an insurer may ask about the nature of the insured’s AI activities, suppliers, controls, exposures and changes over time. A time-bounded evidence-readiness examination can test whether management’s descriptions are supported by records. The insurer decides whether to request, consider or rely on that material; no reviewed source establishes that CFC requires it or attaches a pricing consequence to it.
After an alleged infringement, counsel, the insured and potentially the insurer may need a narrower, event-specific reconstruction: what was retrieved, which model and configuration operated, which output was produced, what a reviewer saw, and when release occurred. Retention established in advance can make that reconstruction possible, but gaps in records are not themselves findings of unlawful conduct.
These purposes overlap, yet a general control assessment is not proof of what happened in a particular transaction. Conversely, a reconstructed transaction does not establish that safeguards generally work. Any independent report should specify its commissioning purpose, intended audience, criteria, examined versions, period, artifacts, procedures, exceptions and limits on reliance.
A disputed marketing asset illustrates the boundary
Illustrative scenario — synthetic, not based on an examined system.
A marketing team uses a third-party generative model and an internal image repository to create a campaign asset. A rights holder later alleges infringement. The organisation retains its supplier contract, the final published image, a dated publication entry and a general approval-policy document. It also has a model-provider identifier and an approval timestamp. However, its retrieval log does not identify the repository image supplied to the model, and the approval record does not preserve the exact image version or supporting context displayed to the reviewer.
An examiner could verify that the retained publication entry identifies the released asset and that an approval event was recorded at a specified time. Without the retrieval identifier and the reviewed-version record, the examiner could not establish which source image entered that generation or whether the reviewer approved the precise version ultimately released. Those propositions remain Unknown on the available evidence. The gaps do not prove unauthorised use, infringement or an ineffective approval, and even a complete reconstruction would not itself determine contractual indemnity, liability or insurance coverage.
Four determinations remain separate: technical behaviour, financial loss, legal liability and insurance coverage. A reliable event record does not itself establish copyright or patent infringement, quantify financial loss, determine legal liability, establish a supplier indemnity obligation or show that a particular policy responds. Those questions require relevant evidence, contract terms, applicable law and competent legal assessment.
Evidence readiness comes before independent assurance spending
Management owns the workflow, controls and records. An examiner can test whether records support identified propositions and report the boundaries of that conclusion. General Counsel advises on rights and legal issues; insurers retain underwriting and pricing discretion. An examiner’s independence, competence, conflicts and permitted reliance should be agreed before commissioning an external opinion.
Evidence retention should be proportionate to the material exposure and applicable privacy, confidentiality, security and preservation obligations. Indefinite retention of every prompt is neither a demonstrated requirement nor a sound default. A controlled record of versions, identifiers, approvals and exceptions may be more useful than an indiscriminate archive.
| Action | Accountable owner | Decision and change condition |
|---|---|---|
| Select one high-consequence AI-assisted IP workflow | Chief Risk Officer and business owner | Identify the entity, output and rights-sensitive activity; broaden only if the chosen boundary omits material exposure |
| Compare the activity with actual insurance and supplier contracts | General Counsel and insurance/risk-transfer owner | Inspect wording, endorsements, restrictions and indemnities; revise any conclusion inconsistent with those terms |
| Test reconstruction using existing records | Technology owner and Chief Information Security Officer | Attempt to follow one output from source through release; prioritise logging and governance where reconstruction fails |
| Set defensible retention and access rules | General Counsel, privacy and security leads | Preserve material evidence within justified legal and security limits; narrow collection when its burden or risk exceeds its use |
| Decide if an independent examination would change a decision | Audit or Risk Committee | Commission only against a defined question and suitable evidence base; defer if records are not yet examinable or no relevant reliance purpose exists |
The decision that can be made now
Practical first step: Select one already released, material AI-assisted asset. Attempt to trace its source inputs and rights records, model and configuration, reviewer-visible version and context, approval decision, and final release record. Mark every unverified link as Unknown; use the result to decide whether retention improvements or an independent examination are justified.
Affirmative AI wording may clarify one insurer’s stated treatment of AI involvement; it cannot establish the facts of an insured’s workflow. Management can now test whether one material AI-assisted activity can be described and reconstructed with existing evidence, then decide whether additional retention or independent examination is proportionate. Whether an insurer would use that evidence in underwriting or claims assessment remains an empirical and contract-specific question. Evidence of a documented underwriting requirement or a specific claim outcome would inform that assessment, without establishing wider market practice.
References
[1] CFC. “CFC launches affirmative AI cover for intellectual property risks.” 23 September 2026. https://www.cfc.com/en-gb/knowledge/news/2026/09/cfc-launches-affirmative-ai-cover-for-intellectual-property-risks/ (accessed 17 October 2026).
[2] CFC. “CFC responds to customer demand for affirmative AI cover.” 25 June 2026. https://www.cfc.com/en-us/knowledge/news/2026/06/cfc-responds-to-customer-demand-for-affirmative-ai-cover/ (accessed 17 October 2026).
[3] CFC. “How AI impacts intellectual property (IP) risk: Your questions answered.” 4 August 2026. https://www.cfc.com/en-us/knowledge/resources/articles/2026/08/how-ai-impacts-intellectual-property-ip-risk-your-questions-answered/ (accessed 17 October 2026).
[4] CFC. “Affirmative AI: How policies respond in action.” 30 September 2026. https://www.cfc.com/en-us/knowledge/resources/articles/2026/09/affirmative-ai-policies-in-action/ (accessed 17 October 2026).
Methodology note
Bounded analysis of four communications from one insurer; activity-to-evidence matrix; illustrative synthetic workflow; separation of pre-bind information, post-event reconstruction, legal liability and contractual coverage. No empirical examination performed.
Notably Absent
The sources reviewed were four CFC publications and one insurance-sector news report. The CFC publications reflect one insurer’s own product communications; no market-wide practice is inferred from them. They did not establish the text or jurisdictional availability of an executed AI-related IP policy, a paid or declined claim under the new wording, or an example showing how that wording responds to AI-assisted marketing publication. They did not establish CFC's actual underwriting evidence requirements, an insurer's acceptance of an ODA3 Institute artifact, a premium or coverage effect attributable to independent provenance review, or market-wide adoption of equivalent wording.
No deployed customer system, independent empirical study, underwriting file or judicial finding was examined. Absence from this bounded search is not evidence that any such material does not exist.
